Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple multivitamin boost birth weights in bangladesh?

NCT ID NCT07540130

First seen Apr 28, 2026 · Last updated Jun 24, 2026 · Updated 10 times

Summary

This study compares a daily multiple micronutrient supplement (MMS) to the standard iron-folic acid supplement in 667 pregnant women in Bangladesh. The main goal is to see if MMS leads to higher infant birth weight. Researchers will also check maternal health, preterm birth rates, and how well women stick to the supplements. Results could help improve nutrition programs for pregnant women in low-resource settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANT WOMEN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • National Institute of Neurosciences & Hospital Dhaka, Bangladesh

    Dhaka, Dhaka Division, 1207, Bangladesh

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

multiple micronutrient supplement (UNIMMAP) vs iron-folic acid

What this could lead to

If successful, this could show that a simple daily supplement with multiple vitamins and minerals is better than iron-folic acid alone for improving birth weight and reducing complications in pregnant women.

What could go wrong

This is an early-phase study in a specific region, so results may not apply elsewhere. The supplements are already known to be safe, but the real-world setting may affect adherence and outcomes.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.